Becton, Dickinson and Company (NYSE:BDX - Get Free Report) EVP Michael David Garrison sold 479 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total value of $94,497.12. Following the sale, the executive vice president now directly owns 4,887 shares in the company, valued at approximately $964,107.36. This trade represents a 8.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Michael David Garrison also recently made the following trade(s):
- On Friday, January 17th, Michael David Garrison sold 597 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $236.51, for a total transaction of $141,196.47.
Becton, Dickinson and Company Stock Down 4.9 %
NYSE:BDX opened at $199.15 on Friday. The company has a market cap of $57.18 billion, a price-to-earnings ratio of 33.08, a P/E/G ratio of 1.63 and a beta of 0.35. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13. The stock's fifty day moving average price is $224.78 and its two-hundred day moving average price is $230.09. Becton, Dickinson and Company has a 52-week low of $193.03 and a 52-week high of $251.99.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. On average, analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.
Becton, Dickinson and Company Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Monday, March 31st. Shareholders of record on Monday, March 10th were given a dividend of $1.04 per share. The ex-dividend date was Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a yield of 2.09%. Becton, Dickinson and Company's payout ratio is presently 69.10%.
Becton, Dickinson and Company announced that its Board of Directors has approved a stock repurchase program on Tuesday, January 28th that allows the company to buyback 10,000,000 shares. This buyback authorization allows the medical instruments supplier to buy shares of its stock through open market purchases. Stock buyback programs are generally an indication that the company's board of directors believes its shares are undervalued.
Analyst Upgrades and Downgrades
BDX has been the subject of several recent analyst reports. StockNews.com raised shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a report on Wednesday, April 2nd. Barclays dropped their price target on Becton, Dickinson and Company from $279.00 to $261.00 and set an "overweight" rating for the company in a report on Monday. Finally, Piper Sandler boosted their price objective on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an "overweight" rating in a research note on Tuesday, January 28th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $275.71.
Get Our Latest Analysis on Becton, Dickinson and Company
Institutional Investors Weigh In On Becton, Dickinson and Company
Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. boosted its stake in Becton, Dickinson and Company by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 26,743,052 shares of the medical instruments supplier's stock valued at $6,067,196,000 after acquiring an additional 184,288 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in shares of Becton, Dickinson and Company by 36.1% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 12,126,707 shares of the medical instruments supplier's stock valued at $2,751,187,000 after purchasing an additional 3,219,317 shares during the period. Geode Capital Management LLC boosted its position in shares of Becton, Dickinson and Company by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 6,351,537 shares of the medical instruments supplier's stock worth $1,437,161,000 after purchasing an additional 66,024 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Becton, Dickinson and Company by 15.1% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 6,175,899 shares of the medical instruments supplier's stock worth $1,401,126,000 after purchasing an additional 810,345 shares during the last quarter. Finally, First Eagle Investment Management LLC grew its stake in shares of Becton, Dickinson and Company by 31.4% during the fourth quarter. First Eagle Investment Management LLC now owns 4,426,022 shares of the medical instruments supplier's stock worth $1,004,132,000 after purchasing an additional 1,057,879 shares during the period. 86.97% of the stock is owned by institutional investors.
About Becton, Dickinson and Company
(
Get Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
